Now let me compile the comprehensive report with all the detailed information.

## DMAA System Duration: Comprehensive Pharmacokinetic Profile
### Complete Pharmacokinetic Profile
**DMAA exhibits a moderate-to-extended elimination profile** compared to many other sympathomimetic stimulants. The foundational pharmacokinetic parameters, established through controlled human studies, provide a clear characterization of the compound's in-vivo behavior.[1][2]

Following a single 25 mg oral dose, DMAA demonstrates consistent absorption and elimination patterns. The **terminal half-life is 8.45 ± 1.9 hours**, representing the time required for plasma concentration to decline by 50% during the elimination phase. This half-life is substantially longer than rapidly metabolized sympathomimetics like p-synephrine (2-3 hours) and comparable to ephedrine (6-7 hours), but shorter than some xanthine derivatives.[2][3][1]

Peak plasma concentration (**Cmax**) reaches approximately **70 ± 16.09 ng/mL** with considerable consistency across subjects, achieved at **3-5 hours post-ingestion (Tmax: 3.57 ± 1.48 hours)**. The lag time—representing the delay in initial plasma appearance—averages **0.14 ± 0.13 hours (approximately 8 minutes)**. This relatively short lag time reflects efficient gastrointestinal absorption of the compound.[1][2]

The **oral clearance rate is 20.02 ± 5 L/hr**, indicating moderate elimination velocity relative to the compound's volume of distribution. The **volume of distribution is notably large at 236 ± 38 L**, substantially exceeding total body water (~42 liters) and plasma volume (~3 liters), indicating extensive tissue distribution and accumulation beyond the vascular compartment. This large Vd explains why DMAA achieves relatively modest plasma concentrations despite its sympathomimetic potency—the compound distributes extensively into peripheral tissues.[4][2][1]

The area under the plasma concentration-time curve (AUC₀₋∞) averages **1204.55 ± 262.89 hr·ng/mL**, reflecting total systemic exposure over the elimination period.[2][1]

### Metabolism Pathway Details
**DMAA undergoes minimal hepatic metabolism**, distinguishing it fundamentally from most other sympathomimetic amines. The vast majority of an orally ingested dose is **excreted unchanged in urine (>90%), with minimal biotransformation occurring in the body**. This characteristic represents a major pharmacokinetic distinction between DMAA and structurally similar compounds like ephedrine (which is metabolized to norephedrine) and p-synephrine (which undergoes extensive hepatic metabolism with only ~2.5% urinary excretion unchanged).[5][6][7][3]

**Hepatic metabolism does not represent a significant elimination pathway for DMAA**. Instead, the compound relies on renal excretion as its primary route of elimination. The urine concentration profile demonstrates maximal DMAA concentration approximately **4 hours post-ingestion with levels of ~18 µg/mL**, confirming the urinary excretion timeline.[6][5]

A notable pharmacological interaction exists regarding **CYP2D6 enzyme inhibition**. DMAA is a **potent inhibitor of cytochrome P450 2D6 (CYP2D6)**, an enzyme responsible for metabolizing numerous therapeutic drugs. This inhibition has clinical significance for potential drug-drug interactions but does not represent the primary metabolic fate of DMAA itself. The compound is not significantly metabolized by CYP2D6 or other major CYP450 enzymes in humans.[5][6]

The simplicity of DMAA's metabolic profile—minimal hepatic transformation coupled with predominant renal excretion—represents an important distinction from classical sympathomimetics and may partially explain its different toxicological profile compared to compounds requiring extensive hepatic metabolism (like MDMA or methamphetamine).[8]

### Factors Affecting Clearance
**Body Composition and Weight**: The study population examining DMAA pharmacokinetics demonstrated heterogeneous body composition (fat mass: 6.1-21.4 kg; total body mass: 68.7-92.8 kg), yet the pharmacokinetic parameters remained relatively consistent, with coefficients of variation ranging from 16-25%. The volume of distribution showed moderate individual variation (235.95 ± 37.82 L), suggesting that larger body mass correlates with proportionally increased distribution space. However, the individual pharmacokinetic parameters from the clinical study demonstrate that among young, healthy males, body composition alone does not dramatically alter peak plasma concentrations (range: 60.23-108.1 ng/mL across subjects).[1][2]

**Age**: The reference pharmacokinetic study enrolled young men (mean age 26.7 ± 4.3 years; range: 23-36 years), and no age-dependent effects on DMAA clearance have been prospectively characterized in different age groups. Age-related alterations in renal function represent the most probable determinant of DMAA clearance differences in older populations, as renal excretion constitutes the primary elimination route. However, clinical data specifically examining geriatric DMAA pharmacokinetics are unavailable.[2][1]

**Renal Function**: As DMAA is excreted unchanged in the urine (>90%), **renal function represents the most significant physiological factor affecting DMAA clearance**. Individuals with reduced glomerular filtration rate (GFR) would be expected to display prolonged half-lives and elevated steady-state plasma concentrations. Conversely, enhanced renal perfusion or clearance would accelerate DMAA elimination. Clinical data from patients with chronic kidney disease have not been published, but the dependence on renal excretion suggests that creatinine clearance would be a primary predictor of DMAA elimination kinetics.

**Hepatic Function**: Given that DMAA undergoes minimal hepatic metabolism, hepatic disease theoretically should not substantially impair DMAA clearance. However, hepatic dysfunction frequently co-exists with renal dysfunction and altered urinary pH, both of which could indirectly affect DMAA clearance. Urinary pH alterations affect the ionization and reabsorption of primary amines; acidic urine promotes ionization and reduced tubular reabsorption, thus accelerating urinary excretion.[6][9][1]

**Urinary pH**: Like other sympathomimetic amines, DMAA's urinary excretion is likely influenced by urinary pH. Acidic urine promotes the ionization of the primary amine group, reducing passive tubular reabsorption and enhancing net urinary excretion. Alkaline urine would promote the non-ionized form, increasing tubular reabsorption and potentially prolonging the elimination half-life. This pH-dependence parallels the well-established effects of urinary pH on ephedrine clearance.[9][1]

**Genetic Factors and CYP2D6 Polymorphisms**: Although DMAA is not significantly metabolized by CYP2D6, inter-individual genetic variation in other renal transporters and metabolic enzymes could theoretically influence DMAA pharmacokinetics. However, these effects have not been systematically investigated. The coefficient of variation in DMAA oral clearance among healthy subjects is 24.96%, indicating moderate interindividual variability, though the specific genetic determinants remain uncharacterized.[10][11][1]

### Detection Window Data from Studies
**Short-to-Moderate Term Detection (24-48 hours)**: Using standard liquid chromatography-mass spectrometry (LC/MS-MS) methods with detection thresholds of 10 ng/mL, DMAA can be reliably detected in urine during the first 24-48 hours following administration. Urinalysis results show detectable levels throughout this period, with laboratories reporting presumptive positive testing at 10 ng/mL and confirmatory positive testing at the same threshold.[12]

**Extended Detection Window (>48 hours)**: Research utilizing sensitive analytical methods has documented substantially extended detection windows. **DART-MS (Direct Analysis in Real-Time Mass Spectrometry)** can detect DMAA in urine **over 48 hours as a means of indicating recent abuse**, with the method demonstrating both rapidity and high mass accuracy for unequivocal identification.[13]

Most significantly, **anti-doping laboratory research by Saudan demonstrated that DMAA could be detected in urine samples up to 105 hours (approximately 4.4 days) following administration of a 40 mg dose**. Even more detailed data from European regulatory sources indicate that **DMAA remained detectable at a concentration of 350 ng/mL after 4 days of initial ingestion**, with the combination of relatively slow absorption and a plasma half-life of 8.4 hours accounting for this prolonged urinary detection window.[14][6]

This extended detection window exceeds that of many other sympathomimetics: p-synephrine is typically undetectable after 4-6 hours due to extensive metabolism, ephedrine detection typically extends to 24-48 hours, and caffeine remains detectable for 24-48 hours depending on the analytical sensitivity employed.[7][3]

The detection window depends critically on analytical methodology:
- **Standard immunoassay/LC-MS-MS at 10 ng/mL threshold**: 24-48 hours typical detection
- **Sensitive LC-MS-MS methods**: 48-72 hours common detection
- **High-sensitivity DART-MS or specialized anti-doping methods**: Up to 105 hours documented
### Comparison to Similar Stimulants
DMAA's pharmacokinetic profile occupies a distinct position within the sympathomimetic class. **p-Synephrine represents the shortest-acting sympathomimetic** with a half-life of 2-3 hours and extensive hepatic metabolism (~97.5% metabolized), resulting in only ~2.5% urinary excretion unchanged and a detection window of approximately 4-6 hours. This rapid clearance reflects its structural class as an indirect sympathomimetic requiring extensive biotransformation.[7][3]

**Ephedrine demonstrates intermediate pharmacokinetics** with a half-life of 6-7 hours—slightly shorter than DMAA—and undergoes metabolic conversion to norephedrine while maintaining a portion of unchanged parent compound excretion in urine. Ephedrine's detection window similarly extends to 24-48 hours. The primary distinction from DMAA is that ephedrine undergoes active hepatic metabolism (producing the norephedrine metabolite), whereas DMAA does not.[3][9]

**Caffeine represents both a structural and kinetic outlier**, with pharmacokinetics highly dependent on individual factors including genetics, smoking status, and oral contraceptive use. Caffeine's half-life ranges from 3-8 hours with mean values around 5 hours in healthy adults. Unlike DMAA and ephedrine, caffeine undergoes extensive hepatic metabolism via CYP1A2 demethylation into multiple metabolites (paraxanthine, theobromine, theophylline) with only metabolite excretion in urine. Its detection window is 24-48 hours with standard toxicological methods.[15][16][17]

**DMAA's minimal metabolism and extensive tissue distribution distinguish it functionally**. The large volume of distribution (236 L) suggests DMAA penetrates tissues substantially—more so than most oral sympathomimetics—contributing to its extended elimination half-life despite moderate oral clearance. The resistance to hepatic metabolism means that hepatic disease or drug interactions affecting hepatic metabolism would not directly alter DMAA kinetics, a pharmacokinetic advantage for patients with liver dysfunction.

However, DMAA's **potent CYP2D6 inhibition capacity** creates potential for drug-drug interactions despite DMAA itself not being metabolized through this pathway. This interaction profile differs from p-synephrine (minimal enzyme interaction) and resembles certain aspects of ephedrine's pharmacology.

***

**Summary**: DMAA exhibits a pharmacokinetic profile characterized by minimal hepatic metabolism, predominant renal excretion (>90% unchanged), a moderate-to-extended terminal half-life of 8.45 hours, and an extended urinary detection window extending up to 105 hours under sensitive analytical conditions. Renal function represents the primary determinant of DMAA clearance, with body composition, urinary pH, and age likely contributing secondary effects. Compared to pharmacologically similar compounds, DMAA's lack of significant hepatic metabolism represents its most distinctive characteristic, though its CYP2D6 inhibition capacity creates clinically relevant drug-drug interaction potential.

[1](https://pubmed.ncbi.nlm.nih.gov/24090077/)
[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3852303/)
[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC7496387/)
[4](https://www.ncbi.nlm.nih.gov/books/NBK545280/)
[5](https://www.benchchem.com/pdf/A_Comparative_Study_of_the_Metabolic_Pathways_of_DMAA_and_Tuaminoheptane.pdf)
[6](https://www.rivm.nl/sites/default/files/2020-07/Fact%20sheet%20DMAA%20DMBA%20%20DMHA_final_20180129_anon.pdf)
[7](https://www.tandfonline.com/doi/full/10.2147/NDS.S144761)
[8](https://pdfs.semanticscholar.org/0b27/d0e1db93b4121044eb58939014e1eaac5d41.pdf?skipShowableCheck=true)
[9](https://www.ncbi.nlm.nih.gov/books/NBK547661/)
[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC6053340/)
[11](https://www.sciencedirect.com/science/article/pii/S0160412021003858)
[12](https://www.labcorp.com/tests/791000/1-3-dimethylamylamine-urine)
[13](https://pubmed.ncbi.nlm.nih.gov/24167149/)
[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC3512447/)
[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC1401099/)
[16](https://comptes-rendus.academie-sciences.fr/biologies/articles/en/10.1016/j.crvi.2006.01.006/)
[17](https://www.efsa.europa.eu/sites/default/files/event/documentset/150305-p09.pdf)
[18](https://www.heraldopenaccess.us/article_pdf/9/1-3-dimethylamylamine-dmaa-a-brief-history-and-review-of-anecdotal-and-laboratory-findings.pdf)
[19](https://www.ijmrhs.com/medical-research/dietary-supplements-containing-aegeline-and-dmaa-13dimethylamylamine-and-their-role-in-liver-injury.pdf)
[20](https://www.sciencedirect.com/topics/medicine-and-dentistry/dimethylamine)
[21](https://www.benchchem.com/pdf/In_vitro_comparison_of_the_vasoconstrictive_properties_of_DMAA_and_ephedrine.pdf)
[22](https://www.benchchem.com/pdf/DMAA_vs_Ephedrine_A_Comparative_Analysis_of_Vasoconstrictor_Potency.pdf)
[23](https://www.sciencedirect.com/science/article/pii/S2214750018306802)
[24](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.692234/full)
[25](https://pmc.ncbi.nlm.nih.gov/articles/PMC7356952/)
[26](https://pubmed.ncbi.nlm.nih.gov/32545708/)
[27](https://pubmed.ncbi.nlm.nih.gov/15060505/)
[28](https://en.wikipedia.org/wiki/Methylhexanamine)
[29](https://www.benchchem.com/pdf/The_Pharmacokinetics_and_Oral_Bioavailability_of_1_3_Dimethylamylamine_DMAA_in_Humans_A_Technical_Guide.pdf)
[30](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657823/)
[31](https://pmc.ncbi.nlm.nih.gov/articles/PMC6696355/)
[32](https://pubs.acs.org/doi/10.1021/acsfoodscitech.1c00427)
[33](https://glenjackson.faculty.wvu.edu/files/d/24ebd828-c6dc-45b8-997e-f683aa711ca3/dart-ms-ms-screening-for-the-determination-of-1-3-dimethylamylamine-and-undeclared-stimulants-in-seized-dietary-supplements-from-brazil.pdf)
[34](https://pmc.ncbi.nlm.nih.gov/articles/PMC3159864/)
[35](https://www.sciencedirect.com/science/article/abs/pii/S0196064412003745)
[36](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/dta.1540)
[37](https://www.hodsdon.com/wiki/uploads/Main/15228165.pdf)
[38](https://pmc.ncbi.nlm.nih.gov/articles/PMC10353075/)
[39](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/synephrine)
[40](https://pmc.ncbi.nlm.nih.gov/articles/PMC3475187/)
[41](https://www.serbiosoc.org.rs/arch/index.php/abs/article/download/5589/pdf_323/0)